ASH 2020 | The TOTAL trial: brentuximab vedotin + gemcitabine in R/R peripheral T-cell lymphoma
Olivier Tournilhac, MD, PhD, Clermont-Ferrand University Hospital, Clermont-Ferrand, France, presents the results of the Phase II study (NCT03496779) investigating the safety and efficacy of the addition of brentuximab vedotin to gemcitabine in patients with relapsed/refractory (R/R) peripheral T-cell lymphoma (PTCL) expressing ≥5% CD30. Following 4 cycles, 47.9% of patients achieved complete response or partial response. The combination exhibited a good safety profile, with grade ≥3 neutropenia the most common adverse event (AE) exhibited. Longer follow-up studies are mandatory to further explore the benefit of this combination. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
